Asked by Gw

Which of the following best describes lenacapavir for the management of PrEP?

All Answers 1

Answered by GPT-5 mini AI
Lenacapavir is a novel long‑acting HIV‑1 capsid inhibitor given by subcutaneous injection (after an initial loading regimen) that can provide protection for months — it’s being developed as a twice‑yearly injectable PrEP option but is investigational for PrEP (not approved for routine PrEP use).